Literature DB >> 23105936

Effect of genetic predisposition on blood lipid traits using cumulative risk assessment in the korean population.

Min Jin Go1, Joo-Yeon Hwang, Dong-Joon Kim, Hye-Ja Lee, Han Byul Jang, Kyung-Hee Park, Jihyun Song, Jong-Young Lee.   

Abstract

Dyslipidemia, mainly characterized by high triglyceride (TG) and low high-density lipoprotein cholesterol (HDL-C) levels, is an important etiological factor in the development of cardiovascular disease (CVD). Considering the relationship between childhood obesity and CVD risk, it would be worthwhile to evaluate whether previously identified lipid-related variants in adult subjects are associated with lipid variations in a childhood obesity study (n = 482). In an association analysis for 16 genome-wide association study (GWAS)-based candidate loci, we confirmed significant associations of a genetic predisposition to lipoprotein concentrations in a childhood obesity study. Having two loci (rs10503669 at LPL and rs16940212 at LIPC) that showed the strongest association with blood levels of TG and HDL-C, we calculated a genetic risk score (GRS), representing the sum of the risk alleles. It has been observed that increasing GRS is significantly associated with decreased HDL-C (effect size, -1.13 ± 0.07) compared to single nucleotide polymorphism combinations without two risk variants. In addition, a positive correlation was observed between allelic dosage score and risk allele (rs10503669 at LPL) on high TG levels (effect size, 10.89 ± 0.84). These two loci yielded consistent associations in our previous meta-analysis. Taken together, our findings demonstrate that the genetic architecture of circulating lipid levels (TG and HDL-C) overlap to a large extent in childhood as well as in adulthood. Post-GWAS functional characterization of these variants is further required to elucidate their pathophysiological roles and biological mechanisms.

Entities:  

Keywords:  childhood obesity; dyslipidemias; genetic risk score; genome-wide association study

Year:  2012        PMID: 23105936      PMCID: PMC3480684          DOI: 10.5808/GI.2012.10.2.99

Source DB:  PubMed          Journal:  Genomics Inform        ISSN: 1598-866X


Introduction

Dyslipidemia is an important etiological factor in the development of cardiovascular disease (CVD), which is the leading cause of deaths for adults. Dyslipidemia is mainly characterized by elevated levels of triglycerides (TGs), increased low-density lipoprotein cholesterol (LDL-C), and reduced high-density lipoprotein cholesterol (HDL-C) [1]. In the past few years, genome-wide association studies (GWASs) and meta-analyses have identified common genetic variants that contribute to blood lipid phenotypes in Caucasian-based populations [2-8]. In addition, we have convincingly mapped 16 loci for major lipoprotein concentrations (TG, HDL-C, and LDL-C) in a two-stage association study in individuals of East Asian ancestry [9]. Given the growing global epidemic of metabolic syndrome, including obesity and type 2 diabetes (T2D), lipoprotein metabolism disorders have become an important health problem in adulthood but also have emerged as an increasingly prevalent risk factor in childhood [10]. Although many GWASs and meta-analyses have provided susceptibility genes or loci for lipid-related traits from multiple large population-based cohorts of adults, it is of great importance to evaluate genetic predisposition at an early age. However, little is known about their genetic effects in a younger population. Moreover, most identified variants have shown modest effects and have explained only a small proportion of heritable components for disease risk [11]. Nevertheless, when multiple genetic markers are considered together, literature-based genetic risk scores might be useful in improving the identification of the genetic contribution in those at high risk of disease [12-14]. Therefore, the aim of this study was to consolidate the associations of GWAS-based candidate variants with blood lipid concentrations in a childhood obesity study and to evaluate genetic risk scores (GRS) for lipid-related risk phenotypes.

Methods

Study subjects

Korean Association Resource (KARE) study was collected through the Korean Genome Epidemiologic Study project - in total, 10,038 people, 40-69 years old, living in Ansung and Ansan, from 2001-2002. For more information, the study has already been reported [9, 15]. The Health Examinee cohort (HEXA) shared project is a community-based epidemiological cohort of 1,200,000 subjects (aged, 40-69) who were recruited for baseline examination from 2004 to 2009. To share the controls, 4,302 subjects were randomly selected to participate between 2006 and 2007. The BioBank Japan study was approved by the ethical committees in the Institute of Medical Science, the University of Tokyo, and the Center for Genomic Medicine, RIKEN. Subjects for the Health2 cohorts for the replication study were selected from another community-based cohort sample provided by the Health2 study, as described previously [15]. We examined 7,861 selected from the 8,500 participants (aged, 40-69). The students aged 9 and 12 years were recruited from Gwacheon City and Gyeonggi Province between April and June 2010. This study was conducted as part of the Korean Children-Adolescents Study (KoCAS), which has been monitored yearly since their entry into elementary school at age 7 in Gwacheon City or fourth grade at age 10 in Seoul and Gyeonggi Province, Korea. Subjects who were enrolled in a specific diet program or were taking any medications known to affect appetite were excluded from the study. The study protocol was approved by the institutional review board of Seoul-Paik Hospital, Inje University, and the Korea Center for Disease Control and Prevention. Informed consent was obtained from the children's parents.

Genotyping

KARE samples were genotyped using Affymetrix Genome-Wide Human SNP array 5.0 (Affymetrix, Santa Clara, CA, USA) and processed by Bayesian Robust Linear Modeling using the Mahalanobis Distance (BRLMM) genotyping algorithm [16]. The HEXA shared sample was genotyped using Affymetrix Genome-Wide Human SNP array 6.0 and processed with the Birdseed Genotyping Algorithm [17]. The BioBank Japan study was genotyped using the Illumina Human610-Quad BeadChip (Illumina Inc., San Diego, CA, USA). A childhood obesity study was genotyped using the Illumina Omni1-Quad BeadChip. Individuals were excluded as follows: genotyping call rate, sex inconsistency, heterozygosity, identity-by-state value, and any kinds of tumor. For more information, the study has been reported [15]. For the replication study in Health2 (7,861), we performed a genotype assay using the TaqMan reaction for four single nucleotide polymorphisms (SNPs) (rs2074356, rs16940212, rs12708980, rs599839) and the GoldenGate assay (Illumina Inc.) for nine SNPs (rs780092, rs10503669, rs2001945, rs603446, rs12686004, rs11216126, rs12229654, rs519113, rs12654264, rs2738446). To analyze the quality control, we conducted duplicate genotyping using 1-2.5% of samples. For further association analyses, concordance rates were satisfied with duplicates of over 99% and a genotype success rate of over 98%.

SNP imputation

In each GWAS data point, imputation analysis was performed using the IMPUTE reference HapMap Asian (Japanese [JPT]/Han Chinese [CHB]) population panel, based on NCBI build 36 and dbSNP build 129. Of these, in each cohort, we dropped SNPs with a posterior probability score < 0.90, high genotype information content (info < 0.5), Hardy-Weinberg equilibrium (HWE) (p < 1 × 10-7), SNP missing rate > 0.1, and minor allele frequency (MAF) < 0.01. In the former analysis, only imputed SNPs that satisfied the genomewide SNP quality control criteria were considered.

Association analysis

In performing the association tests, SNPs were analyzed with PLINK (http://pngu.mgh.harvard.edu/~purcell/plink/) and SAS version 9.1 (SAS institute Inc., Cary, NC, USA). Individuals who were on lipid-lowering therapy and hypertensive medications were excluded for dyslipidemia-related phenotypes, such as TG, HDL-C, and LDL-C. LDL-C concentrations were calculated with Friedewald's formula [18]. Missing values were assigned for individuals with TG over 400 mg/dL. The dyslipidemia-related phenotypes were tested by multivariate linear regression analysis in an additive genetic model (1-d.f.), including age, sex, and recruitment area as covariates. TG and HDL-C were transformed prior to analysis using natural log transformation to remove skewing. LDL-C was normally distributed, and no transformations were required. A GRS was examined using multivariate linear regression analysis, adjusting for age, sex, and recruitment area.

Results

The clinical characteristics and statistics of the variables for each study sample are described in Table 1. Our previous large-scale GWAS identified 9 novel and 24 known genetic loci influencing metabolic traits in East Asians [9]. In an attempt to determine whether well-established lipid-related variants contribute to significant and reproducible genetic factors for susceptibility to blood lipid concentrations in a childhood obesity study, we first examined the associations between individual genetic variants and lipid-related phenotypes using linear regression analysis.
Table 1

Descriptive statistics of variables for each study cohort

KARE, Korea Association Resource study; HEXA, Health Examinee cohort; BBJ, BioBank Japan study; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

aLDL-C is calculated using the Friedewald's formula.

Of these 16 SNPs for blood lipid traits, rs10503669 in LPL (genotyped SNP in a childhood obesity study) was significantly associated with TG and HDL-C, respectively. In addition, rs16940212 in LIPC (linkage disequilibrium-based proxy SNP) was associated with HDL-C (Table 2). The direction of these associations was consistent with our previous GWAS [9].
Table 2

Association between SNPs and lipid-related traits in the population with discovery sets and replication study

A bold indicates significant result.

SNP, single nucleotide polymorphism; CHR, chromosome; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

arsID, LD based SNP; brsID, genetic distant based SNP.

Having two loci (rs10503669 at LPL and rs16940212 at LIPC) showing the strongest association with TG and HDL-C, we next investigated whether the cumulative allelic dosage of risk alleles contributes to the quantitative variation of lipoprotein concentrations in the KARE study using a method of calculating a GRS. We evaluated the joint effects of the best-associated SNPs at the two loci showing evidence of association with HDL-C (rs10503669 at LPL and rs16940212 at LIPC). We calculated a GRS, representing the sum of the risk alleles, and observed that increasing GRS was significantly associated with decreased HDL-C (effect size, -1.13 ± 0.07) compared to SNP combinations without two risk variants (Fig. 1). In addition, a positive correlation was observed between allelic dosage score and risk allele (rs10503669 at LPL) for high TG levels (effect size, 10.89 ± 0.84) (Fig. 2).
Fig. 1

Combined effects of risk alleles on high-density lipoprotein cholesterol (HDL-C). Allelic dosage scores are plotted on the X axis. The histogram (Y axis on left, grey bars) represents the percentage of individuals in each risk allele category. The histogram (Y axis on right, black bars) represents mean HDL-C concentrations. (A) Eight single nucleotide polymorphisms (SNPs) including the risk alleles (rs10503669 at LPL and rs16940212 at LIPC). (B) Six SNPs without the risk alleles (rs10503669 at LPL and rs16940212 at LIPC).

Fig. 2

Combined effects of risk alleles on triglyceride (TG). Allelic dosage scores are plotted on the X axis. The histogram (Y axis on left, grey bars) represents the percentage of individuals in each risk allele category. The histogram (Y axis on right, black bars) represents mean TG concentrations. (A) Five single nucleotide polymorphisms (SNPs) including the risk allele (rs10503669 at LPL). (B) Four SNPs without the risk allele (rs10503669 at LPL).

Discussion

Blood lipid levels are an important etiological contributor to CVD. CVD is the leading cause of death among individuals with T2D, in which lipid abnormalities are characterized by hypertriglyceridemia, reduced levels of HDL-C, and elevated levels of LDL-C. These lipid-related traits, including ~14-54% for TG, ~34-42% for HDL-C, and ~28-50% for LDL-C, are highly heritable in familial T2D or diabetic patients [19, 20]. These estimates indicate that genetic variants play important roles in explaining inter-individual variations in blood lipid levels. Although systematic reviews have reported relationships between childhood obesity and adult CVD risk [21, 22], there is not a shred of evidence that blood lipid status in adults is an independent or dependent risk factor in a childhood obesity group. Early childhood obesity might be the best time for dyslipidemia intervention, including screening, early detection, and management. The aim of this study was to consolidate the associations of 16 GWAS-based candidate variants with blood lipid concentrations across the lifespan. In GWAS-based candidate approaches, the well-known LPL gene was significantly associated with low TG and high HDL-C levels in a childhood obesity study, respectively. This finding is well matched to the negative correlation between blood TG and HDL-C concentrations [23]. In addition, the LIPC gene was further observed in decreased HDL-C. In analyses of the joint effects of these variants, we found that GRSs on the two risk alleles (rs10503669 at LPL and rs16940212 at LIPC) were associated with a cumulative effect of TG and HDL-C levels. However, these facts indicate that currently identified risk variants might have low discriminatory ability and modest genetic contribution to disease prediction [24]. Lipoprotein lipase (LPL) plays an important role in lipid metabolism by hydrolyzing TGs of circulating chylomicrons and very low-density lipoproteins. In addition, LPL is expressed in the brain regions that are functionally relevant to learning, memory, and other cognitive functions. Many GWASs and meta-analyses have shown that variations in the well-known LPL gene for multiple lipid-related traits are implicated in multiethnic populations [2, 3, 9, 25-28]. An increasing number of studies have suggested an association of LPL gene variants with the risk of cerebrovascular as well as CVD [29]. Recent genome-wide investigations identified schizophrenia-associated loci in the chromosome 8p22 region, including LPL [30-32]. It was suggested that LPL is an attractive candidate gene that might be involved in the potential role of lipid metabolism in schizophrenia. Stages of early childhood development can be taken into account when considering a diagnosis of mental illness [33]. Hepatic lipase (LIPC) gene encodes hepatic triglyceride lipase, which is expressed in liver. LIPC has a dual function as a triglyceride hydrolase and ligand/bridging factor for receptor-mediated lipoprotein uptake. A GWAS has identified a possible role of LIPC in advanced age-related macular degeneration (AMD) [34]. AMD is an eye condition affecting the central part of the retina. Although a condition that is commonly associated with the elderly, macular degeneration affects younger people through a rare inherited condition [35]. Based on a lack of direct relationships between HDL-C and AMD risk, the LIPC association may not be the result of an effect on HDL-C levels, but it could represent a pleiotropic effect as a functional component, such as a lipoprotein transporter, underlying the biological mechanisms involving the cholesterol pathway. Taken together, our findings demonstrate that the genetic architecture of circulating lipid levels (TG and HDL-C) overlap to a large extent in childhood as well as in adulthood. A genetic risk assessment by incorporating two risk alleles suggests encouraging evidence that identified genetic risk variants for lipid phenotypes have cumulative effects on lipid concentrations. Post-GWAS functional characterization of these variants is further required to elucidate the pathophysiological role and biological mechanisms.
  35 in total

1.  A genotype calling algorithm for affymetrix SNP arrays.

Authors:  Nusrat Rabbee; Terence P Speed
Journal:  Bioinformatics       Date:  2005-11-02       Impact factor: 6.937

2.  Analysis of quantitative lipid traits in the genetics of NIDDM (GENNID) study.

Authors:  Alka Malhotra; Johanna K Wolford
Journal:  Diabetes       Date:  2005-10       Impact factor: 9.461

3.  Use of the Friedewald formula to estimate LDL-cholesterol in patients with chronic renal failure on dialysis.

Authors:  R Johnson; P McNutt; S MacMahon; R Robson
Journal:  Clin Chem       Date:  1997-11       Impact factor: 8.327

Review 4.  HDL-C and triglyceride levels: relationship to coronary heart disease and treatment with statins.

Authors:  Allan Gaw
Journal:  Cardiovasc Drugs Ther       Date:  2003-01       Impact factor: 3.727

5.  Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels.

Authors:  Richa Saxena; Benjamin F Voight; Valeriya Lyssenko; Noël P Burtt; Paul I W de Bakker; Hong Chen; Jeffrey J Roix; Sekar Kathiresan; Joel N Hirschhorn; Mark J Daly; Thomas E Hughes; Leif Groop; David Altshuler; Peter Almgren; Jose C Florez; Joanne Meyer; Kristin Ardlie; Kristina Bengtsson Boström; Bo Isomaa; Guillaume Lettre; Ulf Lindblad; Helen N Lyon; Olle Melander; Christopher Newton-Cheh; Peter Nilsson; Marju Orho-Melander; Lennart Råstam; Elizabeth K Speliotes; Marja-Riitta Taskinen; Tiinamaija Tuomi; Candace Guiducci; Anna Berglund; Joyce Carlson; Lauren Gianniny; Rachel Hackett; Liselotte Hall; Johan Holmkvist; Esa Laurila; Marketa Sjögren; Maria Sterner; Aarti Surti; Margareta Svensson; Malin Svensson; Ryan Tewhey; Brendan Blumenstiel; Melissa Parkin; Matthew Defelice; Rachel Barry; Wendy Brodeur; Jody Camarata; Nancy Chia; Mary Fava; John Gibbons; Bob Handsaker; Claire Healy; Kieu Nguyen; Casey Gates; Carrie Sougnez; Diane Gage; Marcia Nizzari; Stacey B Gabriel; Gung-Wei Chirn; Qicheng Ma; Hemang Parikh; Delwood Richardson; Darrell Ricke; Shaun Purcell
Journal:  Science       Date:  2007-04-26       Impact factor: 47.728

6.  Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans.

Authors:  Sekar Kathiresan; Olle Melander; Candace Guiducci; Aarti Surti; Noël P Burtt; Mark J Rieder; Gregory M Cooper; Charlotta Roos; Benjamin F Voight; Aki S Havulinna; Björn Wahlstrand; Thomas Hedner; Dolores Corella; E Shyong Tai; Jose M Ordovas; Göran Berglund; Erkki Vartiainen; Pekka Jousilahti; Bo Hedblad; Marja-Riitta Taskinen; Christopher Newton-Cheh; Veikko Salomaa; Leena Peltonen; Leif Groop; David M Altshuler; Marju Orho-Melander
Journal:  Nat Genet       Date:  2008-01-13       Impact factor: 38.330

7.  Newly identified loci that influence lipid concentrations and risk of coronary artery disease.

Authors:  Cristen J Willer; Serena Sanna; Anne U Jackson; Angelo Scuteri; Lori L Bonnycastle; Robert Clarke; Simon C Heath; Nicholas J Timpson; Samer S Najjar; Heather M Stringham; James Strait; William L Duren; Andrea Maschio; Fabio Busonero; Antonella Mulas; Giuseppe Albai; Amy J Swift; Mario A Morken; Narisu Narisu; Derrick Bennett; Sarah Parish; Haiqing Shen; Pilar Galan; Pierre Meneton; Serge Hercberg; Diana Zelenika; Wei-Min Chen; Yun Li; Laura J Scott; Paul A Scheet; Jouko Sundvall; Richard M Watanabe; Ramaiah Nagaraja; Shah Ebrahim; Debbie A Lawlor; Yoav Ben-Shlomo; George Davey-Smith; Alan R Shuldiner; Rory Collins; Richard N Bergman; Manuela Uda; Jaakko Tuomilehto; Antonio Cao; Francis S Collins; Edward Lakatta; G Mark Lathrop; Michael Boehnke; David Schlessinger; Karen L Mohlke; Gonçalo R Abecasis
Journal:  Nat Genet       Date:  2008-01-13       Impact factor: 38.330

8.  Common variants at 30 loci contribute to polygenic dyslipidemia.

Authors:  Sekar Kathiresan; Cristen J Willer; Gina M Peloso; Serkalem Demissie; Kiran Musunuru; Eric E Schadt; Lee Kaplan; Derrick Bennett; Yun Li; Toshiko Tanaka; Benjamin F Voight; Lori L Bonnycastle; Anne U Jackson; Gabriel Crawford; Aarti Surti; Candace Guiducci; Noel P Burtt; Sarah Parish; Robert Clarke; Diana Zelenika; Kari A Kubalanza; Mario A Morken; Laura J Scott; Heather M Stringham; Pilar Galan; Amy J Swift; Johanna Kuusisto; Richard N Bergman; Jouko Sundvall; Markku Laakso; Luigi Ferrucci; Paul Scheet; Serena Sanna; Manuela Uda; Qiong Yang; Kathryn L Lunetta; Josée Dupuis; Paul I W de Bakker; Christopher J O'Donnell; John C Chambers; Jaspal S Kooner; Serge Hercberg; Pierre Meneton; Edward G Lakatta; Angelo Scuteri; David Schlessinger; Jaakko Tuomilehto; Francis S Collins; Leif Groop; David Altshuler; Rory Collins; G Mark Lathrop; Olle Melander; Veikko Salomaa; Leena Peltonen; Marju Orho-Melander; Jose M Ordovas; Michael Boehnke; Gonçalo R Abecasis; Karen L Mohlke; L Adrienne Cupples
Journal:  Nat Genet       Date:  2008-12-07       Impact factor: 38.330

9.  Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts.

Authors:  Yurii S Aulchenko; Samuli Ripatti; Ida Lindqvist; Dorret Boomsma; Iris M Heid; Peter P Pramstaller; Brenda W J H Penninx; A Cecile J W Janssens; James F Wilson; Tim Spector; Nicholas G Martin; Nancy L Pedersen; Kirsten Ohm Kyvik; Jaakko Kaprio; Albert Hofman; Nelson B Freimer; Marjo-Riitta Jarvelin; Ulf Gyllensten; Harry Campbell; Igor Rudan; Asa Johansson; Fabio Marroni; Caroline Hayward; Veronique Vitart; Inger Jonasson; Cristian Pattaro; Alan Wright; Nick Hastie; Irene Pichler; Andrew A Hicks; Mario Falchi; Gonneke Willemsen; Jouke-Jan Hottenga; Eco J C de Geus; Grant W Montgomery; John Whitfield; Patrik Magnusson; Juha Saharinen; Markus Perola; Kaisa Silander; Aaron Isaacs; Eric J G Sijbrands; Andre G Uitterlinden; Jacqueline C M Witteman; Ben A Oostra; Paul Elliott; Aimo Ruokonen; Chiara Sabatti; Christian Gieger; Thomas Meitinger; Florian Kronenberg; Angela Döring; H-Erich Wichmann; Johannes H Smit; Mark I McCarthy; Cornelia M van Duijn; Leena Peltonen
Journal:  Nat Genet       Date:  2008-12-07       Impact factor: 38.330

10.  Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia.

Authors:  Cathryn M Lewis; Douglas F Levinson; Lesley H Wise; Lynn E DeLisi; Richard E Straub; Iiris Hovatta; Nigel M Williams; Sibylle G Schwab; Ann E Pulver; Stephen V Faraone; Linda M Brzustowicz; Charles A Kaufmann; David L Garver; Hugh M D Gurling; Eva Lindholm; Hilary Coon; Hans W Moises; William Byerley; Sarah H Shaw; Andrea Mesen; Robin Sherrington; F Anthony O'Neill; Dermot Walsh; Kenneth S Kendler; Jesper Ekelund; Tiina Paunio; Jouko Lönnqvist; Leena Peltonen; Michael C O'Donovan; Michael J Owen; Dieter B Wildenauer; Wolfgang Maier; Gerald Nestadt; Jean-Louis Blouin; Stylianos E Antonarakis; Bryan J Mowry; Jeremy M Silverman; Raymond R Crowe; C Robert Cloninger; Ming T Tsuang; Dolores Malaspina; Jill M Harkavy-Friedman; Dragan M Svrakic; Anne S Bassett; Jennifer Holcomb; Gursharan Kalsi; Andrew McQuillin; Jon Brynjolfson; Thordur Sigmundsson; Hannes Petursson; Elena Jazin; Tomas Zoëga; Tomas Helgason
Journal:  Am J Hum Genet       Date:  2003-06-11       Impact factor: 11.025

View more
  3 in total

1.  Cumulative risk impact of five genetic variants associated with papillary thyroid carcinoma.

Authors:  Sandya Liyanarachchi; Anna Wojcicka; Wei Li; Malgorzata Czetwertynska; Elzbieta Stachlewska; Rebecca Nagy; Kevin Hoag; Bernard Wen; Rafal Ploski; Matthew D Ringel; Izabella Kozłowicz-Gudzinska; Wojciech Gierlikowski; Krystian Jazdzewski; Huiling He; Albert de la Chapelle
Journal:  Thyroid       Date:  2013-08-29       Impact factor: 6.568

2.  The Relationship of Dietary Pattern and Genetic Risk Score with the Incidence Dyslipidemia: 14-Year Follow-Up Cohort Study.

Authors:  Seon-Joo Park; Myung-Sunny Kim; Sang-Woon Choi; Hae-Jeung Lee
Journal:  Nutrients       Date:  2020-12-16       Impact factor: 5.717

3.  Prediction of cholesterol ratios within a Korean population.

Authors:  Jin Sol Lee; Hyun Sub Cheong; Hyoung Doo Shin
Journal:  R Soc Open Sci       Date:  2018-01-17       Impact factor: 2.963

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.